Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BHV3000-310: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine

NCT04574362 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04574362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04574362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BHV3000-310: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
October 22, 2020
Completion date
December 16, 2021
Enrollment
1,648 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

acute migraine